SPHDF (Santhera Pharmaceuticals Holding AG) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $35.65
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 34.8% below its estimated GF Value™ of $35.65.

Key valuation signals for SPHDF:

  • Dividends Received:
  • GF Value™: $35.65 vs. price of $23.25 (34.8% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$35.65
GF Value